Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Type 2 diabetes presents a growing global health burden with significant morbidity and mortality.
• Existing treatments often have limitations, necessitating the development of novel therapeutic approaches.

Purpose of the Study:

• To investigate the potential of serotonin 2C receptor (5-HT(2C)R) agonists in improving glucose homeostasis.
• To determine if 5-HT(2C)R agonists can enhance glucose tolerance independently of effects on body weight or appetite.

Main Methods:

• Utilized murine models of obesity and type 2 diabetes.
• Administered 5-HT(2C)R agonists and assessed effects on glucose tolerance, plasma insulin, ingestive behavior, energy expenditure, and body composition.
• Investigated the role of melanocortin receptors (MC4Rs and MC3Rs) in mediating the observed effects.

Main Results:

• 5-HT(2C)R agonists significantly improved glucose tolerance and reduced plasma insulin levels in diabetic mice.
• These metabolic improvements occurred at agonist concentrations that did not affect body weight, fat mass, or ingestive behavior.
• The glucose-lowering effects were dependent on the activation of melanocortin-4 receptors (MC4Rs).

Conclusions:

• Pharmacological targeting of 5-HT(2C)Rs offers a promising strategy for enhancing glucose tolerance.
• This approach may provide a novel therapeutic avenue for type 2 diabetes treatment, independent of weight loss.
• The findings highlight a distinct mechanism involving MC4R activation for glucose regulation.